|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Zeng H and Zhang S:
Epidemiology of lung cancer in China. Thorac Cancer. 6:209–215.
2007. View Article : Google Scholar
|
|
3
|
Arriagada R, Bergman B, Dunant A, Le
Chevalier T, Pignon JP and Vansteenkiste J; International Adjuvant
Lung Cancer Trial Collaborative Group, : Cisplatin-based adjuvant
chemotherapy in patients with completely resected non-small-cell
lung cancer. N Engl J Med. 350:351–360. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang T, Nelson RA, Bogardus A and Grannis
FW Jr: Five-year lung cancer survival: Which advanced stage
nonsmall cell lung cancer patients attain long-term survival?
Cancer. 116:1518–1525. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Luster AD: Chemokines-chemotactic
cytokines that mediate inflammation. N Engl J Med. 338:436–445.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Harrison JK, Fong AM, Swain PA, Chen S, Yu
YR, Salafranca MN, Greenleaf WB, Imai T and Patel DD: Mutational
analysis of the fractalkine chemokine domain. Basic amino acid
residues differentially contribute to CX3CR1 binding, signaling,
and cell adhesion. J Biol Chem. 276:21632–21641. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ludwig A and Weber C: Transmembrane
chemokines: Versatile ‘special agents’ in vascular inflammation.
Thromb Haemost. 97:694–703. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bazan JF, Bacon KB, Hardiman G, Wang W,
Soo K, Rossi D, Greaves DR, Zlotnik A and Schall TJ: A new class of
membrane- bound chemokine with a CX3C motif. Nature. 385:640–644.
1997. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Haskell CA, Cleary MD and Charo IF: Unique
role of the chemokine domain of fractalkine in cell capture.
Kinetics of receptor dissociation correlate with cell adhesion. J
Biol Chem. 275:34183–34189. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fonovic UP, Jevnikar Z and Kos J:
Cathepsin S generates soluble CX3CL1 (fractalkine) in vascular
smooth muscle cells. Biol Chem. 394:1349–1352. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Marchesi F, Locatelli M, Solinas G, Erreni
M, Allavena P and Mantovani A: Role of CX3CR1/CX3CL1 axis in
primary and secondary involvement of the nervous system by cancer.
J Neuroimmunol. 224:39–44. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tsang JY, Ni YB, Chan SK, Shao MM, Kwok
YK, Chan KW, Tan PH and Tse GM: CX3CL1 expression is associated
with poor outcome in breast cancer patients. Breast Cancer Res
Treat. 140:495–504. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Andre F, Cabioglu N, Assi H, Sabourin JC,
Delaloge S, Sahin A, Broglio K, Spano JP, Combadiere C, Bucana C,
et al: Expression of chemokine receptors predicts the site of
metastatic relapse in patients with axillary node positive primary
breast cancer. Ann Oncol. 17:945–951. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zheng J, Yang M, Shao J, Miao Y, Han J and
Du J: Chemokine receptor CX3CR1 contributes to macrophage survival
in tumor metastasis. Mol Cancer. 12:1412013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim M, Rooper L, Xie J, Kajdacsy-Balla AA
and Barbolina MV: Fractalkine receptor CX3CR1 is
expressed in epithelial ovarian carcinoma cells and required for
motility and adhesion to peritoneal mesothelial cells. Mol Cancer
Res. 10:11–24. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shulby SA, Dolloff NG, Stearns ME, Meucci
O and Fatatis A: CX3CR1-fractalkine expression regulates cellular
mechanisms involved in adhesion, migration, and survival of human
prostate cancer cells. Cancer Res. 64:4693–4698. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Celesti G, Di Caro G, Bianchi P, Grizzi F,
Marchesi F, Basso G, Rahal D, Delconte G, Catalano M, Cappello P,
et al: Early expression of the fractalkine receptor CX3CR1 in
pancreatic carcinogenesis. Br J Cancer. 109:2424–2433. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yao X, Qi L, Chen X, Du J, Zhang Z and Liu
S: Expression of CX3CR1 associates with cellular migration,
metastasis, and prognosis in human clear cell renal cell carcinoma.
Urol Oncol. 32:162–170. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2ΔΔCT method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Garton KJ, Gough PJ, Blobel CP, Murphy G,
Greaves DR, Dempsey PJ and Raines EW: Tumor necrosis
factor-alpha-converting enzyme (ADAM17) mediates the cleavage and
shedding of fractalkine (CX3CL1). J Biol Chem. 276:37993–38001.
2001.PubMed/NCBI
|
|
21
|
Shiraishi K, Fukuda S, Mori T, Matsuda K,
Yamaguchi T, Tanikawa C, Ogawa M, Nakamura Y and Arakawa H:
Identification of fractalkine, a CX3C-type chemokine, as a direct
target of p53. Cancer Res. 60:3722–3726. 2000.PubMed/NCBI
|
|
22
|
Imai T, Hieshima K, Haskell C, Baba M,
Nagira M, Nishimura M, Kakizaki M, Takagi S, Nomiyama H, Schall TJ,
et al: Identification and molecular characterization of fractalkine
receptor CX3CR1, which mediates both leukocyte migration
and adhesion. Cell. 91:521–530. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hou SM, Hou CH and Liu JF: CX3CL1 promotes
MMP-3 production via the CX3CR1, c-Raf, MEK, ERK, and NF-κB
signaling pathway in osteoarthritis synovial fibroblasts. Arthritis
Res Ther. 19:2822017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ideker T, Thorsson V, Ranish JA, Christmas
R, Buhler J, Eng JK, Bumgarner R, Goodlett DR, Aebersold R and Hood
L: Integrated genomic and proteomic analyses of a systematically
perturbed metabolic network. Science. 292:929–934. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tardaguila M, Mira E, Garcia-Cabezas MA,
Feijoo AM, Quintela-Fandino M, Azcoitia I, Lira SA and Mañes S:
CX3CL1 promotes breast cancer via transactivation of the EGF
pathway. Cancer Res. 73:4461–4473. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Thomas SM and Brugge JS: Cellular
functions regulated by Src family kinases. Annu Rev Cell Dev Biol.
13:513–609. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Roskoski R Jr: Src protein-tyrosine kinase
structure, mechanism, and small molecule inhibitors. Pharmacol Res.
94:9–25. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Parsons JT, Martin KH, Slack JK, Taylor JM
and Weed SA: Focal adhesion kinase: A regulator of focal adhesion
dynamics and cell movement. Oncogene. 19:5606–5613. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang X, Chattopadhyay A, Ji QS, Owen JD,
Ruest PJ, Carpenter G and Hanks SK: Focal adhesion kinase promotes
phospholipase C-gamma1 activity. Proc Natl Acad Sci USA.
96:9021–9026. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chang YM, Bai L, Liu S, Yang JC, Kung HJ
and Evans CP: Src family kinase oncogenic potential and pathways in
prostate cancer as revealed by AZD0530. Oncogene. 27:6365–6375.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Green TP, Fennell M, Whittaker R, Curwen
J, Jacobs V, Allen J, Logie A, Hargreaves J, Hickinson DM,
Wilkinson RW, et al: Preclinical anticancer activity of the potent,
oral Src inhibitor AZD0530. Mol Oncol. 3:248–261. 2009. View Article : Google Scholar : PubMed/NCBI
|
